Allergies News and Research

Latest Allergies News and Research

Consumer-friendly "finger stick" blood test to detect cardiovascular disease is broadly available now

A new blood test, measuring the level of omega-3 fatty acids in red blood cells, is now broadly available for the first time to the public everywhere as a consumer-friendly, at-home "finger stick" test. While scientists have long known of the benefits of fish and fish oil for overall heart health, over the past decade research has proven that the omega-3 fatty acids found in fish dramatically reduce one's risk for cardiovascular disease. Further, recent research indicates that omega-3 levels may be among the best predictors of future coronary heart disease - providing much stronger correlations to the risk of sudden cardiac death than traditional indicators, including HDL and LDL cholesterol.

20 Aug 2009

UT Southwestern Medical Center: Human gut bacteria ward off Toxoplasma gondii

Immunology researchers at UT Southwestern Medical Center have found that bacteria present in the human gut help initiate the body's defense mechanisms against Toxoplasma gondii, the parasite responsible for toxoplasmosis.

20 Aug 2009

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Inovio Biomedical Corporation (NYSE AMEX: INO) (“Inovio”) today reported financial results for the three and six months ended June 30, 2009. Total revenue of $2.5 million and $2.9 million for the three and six months ended June 30, 2009, compared to $663,000 and $1.3 million for the three and six months ended June 30, 2008, respectively.

20 Aug 2009

U.S.District Court ruling favors Merck in patent infringement suit against Teva Pharmaceuticals

Merck & Co., Inc. announced today that the U.S. District Court for the District of New Jersey has ruled in Merck's favor in a patent infringement suit against Teva Pharmaceuticals USA Inc. (Teva).

20 Aug 2009

FDA approves Hiberix Haemophilus influenzae type b vaccine

In response to a U.S. shortage of a vaccine to protect infants from Haemophilus influenzae type b (Hib), GlaxoSmithKline (NYSE: GSK) has received accelerated approval from the FDA (Food and Drug Administration) for Hiberix((R)) [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)] as a booster dose in children 15 months through four years of age. Hib is an often severe and potentially deadly bacterial infection that can cause meningitis.

19 Aug 2009

U.S. Food and Drug Administration launches new Center for Tobacco Products

The U.S. Food and Drug Administration today launched its new Center for Tobacco Products in an historic effort to curb the hundreds of thousands of deaths caused by those products each year.

19 Aug 2009

H1N1 vaccine orders top 1 billion, WHO Says

"Northern hemisphere countries have so far ordered more than one billion doses of swine flu vaccine, the World Health Organisation said Tuesday, sparking warnings over shortages," Agence France-Presse reports. While some countries, including Greece, The Netherlands, Canada and Israel, have ordered enough vaccine to inoculate their citizens, "[o]thers, such as Germany, the United States, Britain and France, have put in orders that would cover between 30 and 78 percent of people," the news service writes.

19 Aug 2009

Amira Pharmaceuticals submits IND for inflammatory and allergic disease treatment candidate

Amira Pharmaceuticals, Inc. announced today the submission of an Investigational New Drug application (IND) of AM461, its internally-discovered, oral drug candidate for the treatment and control of inflammatory and allergic disease linked to the arachidonic acid pathway, to the U.S. Food and Drug Administration.

19 Aug 2009

Two American Oriental Bioengineering products bag China's Top Branded Drugs of 2009 award

American Oriental Bioengineering, Inc. today announced that two of AOBO's branded products, Jinji Capsules and Boke Nasal Spray, were awarded the designation of "China's Top Branded Drugs of 2009" at an award ceremony held in Shanghai on August 11, 2009.

19 Aug 2009

FDA approves Extavia for multiple sclerosis

The US Food and Drug Administration (FDA) has approved Extavia(R) (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease.

17 Aug 2009

Keeping asthma under control

A new nationwide telephone survey of 1,001 asthma patients, conducted by AstraZeneca, found that while most patients with asthma understand the risks associated with uncontrolled asthma, they don't always act accordingly.

16 Aug 2009

Pharmathene reports Q2 2009 financials

PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the second quarter and six months ended June 30, 2009.

14 Aug 2009

Outdoor air pollutants at high levels

Higher summertime levels of outdoor ground-level ozone, microscopic particle pollution like smoke and smog, as well as other air pollutants may cause anyone who is sensitive to these airborne contaminants to experience shortness of breath, wheezing and coughing, and may also trigger asthma attacks and cause lung irritation.

12 Aug 2009

Past flu pandemics help predict the future course of 2009 H1N1 virus

A commonly held belief that severe influenza pandemics are preceded by a milder wave of illness arose because some accounts of the devastating flu pandemic of 1918-19 suggested that it may have followed such a pattern.

12 Aug 2009

Schering-Plough announces agreement with Orchid Chemicals & Pharmaceuticals on generic forms of CLARINEX

Schering-Plough Corporation (NYSE: SGP) today announced an agreement with Orchid Chemicals & Pharmaceuticals Ltd. and Orgenus Pharma, Inc. ("Orchid"), related to the generic manufacturing of certain formulations of CLARINEX(R) (desloratadine).

12 Aug 2009

Retrovirox receives another NIH grant for novel inhibitors of HIV entry

RetroVirox, Inc., a biotechnology company specializing in the development of novel antivirals, announced today that it has received a grant award of $296,875 from the National Institute of Allergy and Infectious Disease (NIAID), of the National Institutes of Health (NIH). This is the second award to RetroVirox from the NIH in less than six months. In March 2009 the company received its first grant to develop novel inhibitors of HIV entry.

12 Aug 2009

Experimental treatment for multiple sclerosis reverses disorder in mice

A new experimental treatment for multiple sclerosis (MS) completely reverses the devastating autoimmune disorder in mice, and might work exactly the same way in humans, say researchers at the Jewish General Hospital Lady Davis Institute for Medical Research and McGill University in Montreal.

11 Aug 2009

New personal assistance voice dialer for seniors who need to call for help in an emergency

eMed-ID, the world's first emergency medical device franchise, announced today the launch of eMed-Alert, a next-generation personal assistance voice dialer designed for seniors who may need to call for help in an emergency. With more than 11 million Americans age 65 and older living alone today, eMed-Alert provides seniors a way to maintain their independence.

11 Aug 2009

Aldose reductase inhibition shows promise for asthma

University of Texas Medical Branch at Galveston researchers have found that a single enzyme is apparently critical to most allergen-provoked asthma attacks - and that activity of the enzyme, known as aldose reductase, can be significantly reduced by compounds that have already undergone clinical trials as treatments for complications of diabetes.

11 Aug 2009

Eiger Biopharmaceuticals starts CLEAN-1 HCV phase 1B trial

Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus (HCV). The trial, run in centers in Australia and New Zealand, will investigate the antiviral effect of clemizole monotherapy in the absence of interferon.

10 Aug 2009